rituximab

Overview

Rituximab is a chimeric monoclonal antibody used as a therapeutic agent that depletes B lymphocytes. It binds the CD20 antigen on the surface of B cells and triggers their destruction through mechanisms including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis, producing a sustained depletion of circulating and tissue B cells. Because CD20 is expressed across most stages of B-cell development but not on stem cells or terminally differentiated plasma cells, rituximab reduces antibody-mediated and B-cell–driven immune activity while sparing the capacity to reconstitute the B-cell compartment. Peripheral CD19+ B-cell counts are commonly followed as a pharmacodynamic marker of the depth and duration of this depletion.

Clinically, rituximab is established in CD20-positive hematologic malignancies, particularly B-cell non-Hodgkin lymphomas such as follicular lymphoma, where it is combined with chemotherapy agents including cyclophosphamide, doxorubicin, vincristine, bendamustine, and lenalidomide, and where newer regimens pair it with agents such as the CD3×CD20 bispecific antibody epcoritamab. Its B-cell–depleting action has also made it a mainstay of many antibody-mediated and autoimmune conditions, including IgA vasculitis with glomerulonephritis, and neuroinflammatory diseases such as multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease, where it is often used alongside or in place of other anti-CD20 or anti-CD19 antibodies such as ocrelizumab and inebilizumab. Because prolonged B-cell depletion blunts humoral immunity, rituximab therapy also carries recognized implications for vaccine responsiveness and infection risk.

Recent Publications Summary

Rituximab efficacy in hematologic malignancies was demonstrated across maintenance and combination therapeutic strategies. In mantle cell lymphoma, rituximab maintenance therapy was associated with improved five-year overall survival in a population-based cohort, with survival rates increasing from 38% (1989-2000) to 60% (2015-2020) coinciding with rituximab maintenance implementation 41637634Feb. In relapsed/refractory follicular lymphoma, combination therapy with epcoritamab, lenalidomide, and rituximab (R2) achieved superior response rates compared to rituximab-based chemoimmunotherapy alone, with overall response rates of 96.9% versus 80.5% and complete response rates of 90.2% versus 55.1%, along with significantly prolonged duration of response 42415230Jul. Population pharmacokinetic modeling in treatment-naïve diffuse large B-cell lymphoma patients identified albumin-globulin ratio as a significant covariate affecting rituximab clearance and drug exposure during induction therapy 42499290Jul.

Clinical evaluation of rituximab in neuroinflammatory disorders expanded through head-to-head comparisons and real-world evidence. A head-to-head comparison assessed rituximab versus ocrelizumab in newly diagnosed relapsing multiple sclerosis 42384870Jul. Real-world multicenter data compared low-dose rituximab with inebilizumab (an anti-CD19 monoclonal antibody) in neuromyelitis optica spectrum disorders 42044464Apr, and emerging evidence supports the long-term efficacy and safety of rituximab maintenance therapy in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease 41894908Mar. A pediatric case report documented the transition to rituximab in a patient with concurrent neurofibromatosis type 1 and multiple sclerosis diagnosed by updated 2024 criteria despite the absence of clinical demyelinating symptoms 42485588Jul.

Rituximab demonstrated clinical utility in renal and systemic diseases. In primary membranous nephropathy, the protein selectivity index (PSI) emerged as a predictor of rituximab response, with low-PSI patients (<0.303) achieving significantly higher complete remission rates compared to high-PSI patients (59.65% vs. 12.50%, p = 0.001) 42535733Jul. Single-dose rituximab induction therapy achieved favorable renal response in a patient with severe IgA vasculitis and rapidly progressive glomerulonephritis unresponsive to glucocorticoid pulse therapy and intravenous cyclophosphamide 42050300Apr. Cutaneous improvements in sclerosis were observed in systemic sclerosis patients treated with rituximab in a real-world Indian cohort 40971877Sep.

Mechanistic investigations elucidated rituximab's molecular interactions and clinical applicability. Surface-based affinity analysis demonstrated that optimal inter-CD20 spacing of approximately 2 nanometers facilitates efficient rituximab binding through CD20 dimer formation and secondary antibody-antibody interactions 42331022Jun. Advanced mass spectrometry methods enabled rapid absolute quantitation of rituximab in human plasma from chronic lymphocytic leukemia patients, supporting clinical monitoring applications 42113895May.

What Changes, What Holds

1. Rituximab’s benefit now extends to maintenance strategies and newer combinations, but the core role remains unchanged
REINFORCES The new hematologic data strengthen the established view of rituximab as an effective component of CD20-positive lymphoma therapy, including in maintenance settings and in combination with other agents. The improved outcomes in mantle cell lymphoma and relapsed/refractory follicular lymphoma do not displace the baseline account; they mainly broaden the evidence base for how rituximab is deployed. 41637634Feb42415230Jul

2. Comparative data now place rituximab alongside other anti-CD20 and anti-CD19 options in neuroinflammatory disease
NEW DIRECTION Head-to-head and real-world comparisons add a practical layer to the baseline’s statement that rituximab is used in multiple neuroinflammatory disorders. These studies do not overturn that role, but they shift the question from whether rituximab works to how it performs relative to ocrelizumab and inebilizumab, and whether maintenance can sustain benefit in MOG antibody-associated disease. The pediatric case mainly illustrates expanded diagnostic context rather than a new indication. 42384870Jul42044464Apr

3. Response prediction is becoming more individualized in renal and systemic disease
NEW DIRECTION The renal and systemic reports leave rituximab’s established uses intact, but they add a clinically useful layer: patient features may help predict who benefits most. That matters most for primary membranous nephropathy, where the protein selectivity index appears to stratify response, while the IgA vasculitis case and systemic sclerosis cohort mainly reinforce ongoing off-label use in immune-mediated disease. 42535733Jul42050300Apr

4. Rituximab research is moving toward mechanistic spacing rules and direct plasma quantitation
METHOD These findings change how rituximab is studied and monitored rather than what is known about its clinical roles. The CD20-spacing work refines a molecular model for binding efficiency, and the mass spectrometry assay supports faster absolute drug measurement in plasma. Neither result alters the baseline account of B-cell depletion, but both could improve pharmacology studies and therapeutic monitoring. 42331022Jun42113895May

Overview update candidates: maintenance benefit in mantle cell lymphoma; improved activity in combination regimens for relapsed/refractory follicular lymphoma; comparative effectiveness versus ocrelizumab and inebilizumab; long-term maintenance use in relapsing MOG antibody-associated disease; response prediction in primary membranous nephropathy; continued use in severe IgA vasculitis with glomerulonephritis and systemic sclerosis.